Compare Amylx Pharmaceuticals Inc (AMLX) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Equinix Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Equinix Inc trades at $1,032.41 (market cap $102.95B). The key difference: Equinix Inc is far larger — about 40.7× Amylx Pharmaceuticals Inc's market cap, and Equinix Inc pays a 1.98% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EQIX | |
|---|---|---|
Market Cap | $2.53B | $102.95B |
Sector | Health | Real Estate |
52-Week High | $24.19 | $1.12K |
52-Week Low | $7.82 | $726.09 |
Enterprise Value | $2.28B | $124.08B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Equinix (EQIX) trades at $1,042.62, down 0.97% on the day, with strong analyst support (74.5% buy ratings) and a consensus price target of $1,120. The stock shows bullish technical signals with support at $1,040 and resistance at $1,067. Recent Q2 2026 earnings beat expectations with $4.83 EPS versus $4.73 expected, while revenue growth continues at 9.2B in 2025 with improving net margins to 15.63%. The company maintains robust cash flow from operations at $3.9B despite significant capital investments.
EQIX presents a compelling growth story driven by AI infrastructure demand and global digital expansion, though elevated valuation multiples (P/E 67.09) and substantial debt levels ($15.2B total debt) warrant caution. The stock offers dividend income with recent $5.16 payments, but investors should monitor execution risks in capital-intensive expansion and competitive pressures in the data center REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
